Advertisement

Topics

Adenosine Therapeutics,LLC Company Profile

12:53 EST 13th December 2018 | BioPortfolio

Adenosine Therapeutics (AT), located in Charlottesville, VA, is a drug discovery and development company that was co-founded in 1999 by University of Virginia (UVa) Professor, Joel Linden and entrepreneur, Robert Capon (one of three cofounders of Virologic, NASDAQ: VLGC.) Although relatively young as a company, AT represents the fruition of over 40 years of academic research at UVa on the pharmacology and physiology of the endogenous neucleoside, adenosine. UVa's establishment as the academic leader in adenosine research began with the work of Dr. Robert Berne in the 1960s. This led to the patent, clinical development, and successful marketing of the anti-arrhythmic, Adenocard®, a staple in ambulances and paramedic kits.

Location

P.O. Box 4632
Charlottesville
Virginia
22905
United States of America

Contact

Phone: (434) 220.9400
Fax: (434) 971.6912
Email: sabbott@adenrx.com


News Articles [737 Associated News Articles listed on BioPortfolio]

AdoRx brings in $10mm through Series A round

Epidarex Capital and CRT Pioneer Fund invested $10mm in AdoRx Therapeutics Ltd.'s Series A round. The company is developing adenosine pathway antagonists for cancer and has two preclinical candidates ...

Structure of the adenosine-bound human adenosine A1 receptor–Gi complex

FDA Approves Revcovi for Adenosine Deaminase SCID

The US Food and Drug Administration has approved elapegademase-lvlr for the treatment of adults and children with adenosine deaminase severe combined immune deficiency. FDA Approvals

Adenosine Receptor A3 ADORA3 Pipeline Review, H2 2018 [Report Updated: 28092018] Prices from USD $3500

Adenosine Receptor A3 ADORA3 Pipeline Review, H2 2018SummaryAdenosine Receptor A3 ADORA3 pipeline Target constitutes close to 17 molecules. Out of which approximately 16 molecules are developed by co...

MiR-27b regulates podocyte survival through targeting adenosine receptor 2B in podocytes from non-human primate

ITeos closes $75mm Series B round

Cancer immunotherapies firm iTeos Therapeutics SA raised $75mm through an oversubscribed Series B round led by new investor MPM Capital. Additional new participants included HBM Partners, 6 Dimensions...

New A2A Receptor Study Offers Insights on Memory Loss Associated with Aging

An international team says it has described a new mechanism involved in memory loss associated with aging. Their study (“ Age-Related Shift in LTD Is Dependent on Neuronal Adenosine A 2A Receptors I...

New A2A Receptor Study Offers Insights on Memory Loss Associated with Aging

An international team says it has described a new mechanism involved in memory loss associated with aging. Their study (“ Age-Related Shift in LTD Is Dependent on Neuronal Adenosine A 2A Receptors I...

PubMed Articles [660 Associated PubMed Articles listed on BioPortfolio]

Targeting the CD73-adenosine axis in immuno-oncology.

The ectonucleotidases CD39 and CD73 are cell surface enzymes that catabolize the breakdown of extracellular ATP into adenosine. As such, they constitute critical components of the extracellular purine...

The role of adenosine in epilepsy.

Adenosine is a well-characterized endogenous anticonvulsant and seizure terminator of the brain. Through a combination of adenosine receptor-dependent and -independent mechanisms, adenosine affects se...

Adenosine signalling and the immune system: when a lot could be too much.

Adenosine is increasingly recognized as a key mediator of the immune response. Signals delivered by extracellular adenosine are detected and transduced by G-protein-coupled cell-surface receptors, cla...

Adenosine role in brain functions: Pathophysiological influence on Parkinson's disease and other brain disorders.

Although adenosine plays a key role in multiple motor, affective, and cognitive processes, it has received less attention in the neuroscience field compared to other neurotransmitters (e.g., dopamine)...

Ability of γδ T cells to modulate the Foxp3 T cell response is dependent on adenosine.

Whether γδ T cells inhibit or enhance the Foxp3 T cell response depends upon their activation status. The critical enhancing effector in the supernatant is adenosine. Activated γδ T cells express ...

Clinical Trials [357 Associated Clinical Trials listed on BioPortfolio]

AMP as a Better Delivery System of Adenosine

Adenosine and AMP are substances normally present in the body. Adenosine is also given for the treatment of some heart rhythm problems and may be used to reduce heart damage during heart ...

Role of Adenosine in the Release of VEGF and Cytokines

The purpose of this study is to extend previous observations in animal models regarding the effects of adenosine in the release of cytokines to human subjects. We intend to accomplish this...

The Effect of Rosuvastatin on Adenosine Metabolism

The aim of this study is to show whether rosuvastatin influences adenosine metabolism. Therefore we will determine whether rosuvasatin increases dipyridamole-induced vasodilation by increa...

Effect of Polymorphisms in the Adenosine a2a Receptor Gene and AMPD2 Gene on Adenosine-Induced Vasodilation and Reactive Hyperemia

The endogenous nucleoside adenosine can induce various cardiovascular and neurohumoral effects by stimulation of specific adenosine receptors. taken together these effects protect against ...

Circulating Adenosine Levels Before and After IV Persantine

Persantine is a drug that is routinely used to determine blood flow to the heart in the diagnosis of coronary heart disease. Persantine causes an increase in the adenosine level in the blo...

Companies [1293 Associated Companies listed on BioPortfolio]

Adenosine Therapeutics,LLC

Adenosine Therapeutics (AT), located in Charlottesville, VA, is a drug discovery and development company that was co-founded in 1999 by University of Virginia (UVa) Professor, Joel Linden and entrepre...

Inotek Pharmaceuticals Corp.

Inotek Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for glaucoma and other eye diseases. ...

PeriCor Therapeutics, Inc.

PeriCor Therapeutics, Inc. is a privately-held specialty biopharmaceutical company focused on the development and commercialization of a new class of medicines, adenosine regulating agents, to improve...

Duska Therapeutics, Inc.

Duska Therapeutics, Inc. (Duska) is a specialty pharmaceutical company that develops new cardiovascular medicines based upon the emerging new pharmacology of adenosine triphosphate (ATP) and nitri...

Medco Research Incorporated

Medco Research, Inc. is a pharmaceutical company dedicated to being a leader in the global commercialization of cardiovascular medicines and adenosine-receptor technologies leading to superior gr...

More Information about "Adenosine Therapeutics,LLC" on BioPortfolio

We have published hundreds of Adenosine Therapeutics,LLC news stories on BioPortfolio along with dozens of Adenosine Therapeutics,LLC Clinical Trials and PubMed Articles about Adenosine Therapeutics,LLC for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Adenosine Therapeutics,LLC Companies in our database. You can also find out about relevant Adenosine Therapeutics,LLC Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...


Corporate Database Quicklinks



Searches Linking to this Company Record